English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAntibody Response to SARS-CoV-2 Vaccination in Children and Adolescents Higher than Adults
Researchers led by PhD candidate Mary Kathryn Bohn of the Hospital for Sick Children in Toronto, Canada, have found that children tend to have higher antibody levels against the SARS-CoV-2 virus following administration of mRNA vaccines than adults.
Bohn’s study enrolled 644 vaccinated participants (312 adults and 332 children) who ranged in age from 6-79 years, along with a control group of 168 individuals with no history of SARS-CoV-2 infection or vaccination. The researchers assessed participants’ blood samples using two commercially available coronavirus antibody tests.
The results from this showed that the mean antibody level (± standard deviation) in pediatric participants was 2,037 ± 1,515 binding antibody units/mL, while in adult participants it was only 1,444 ± 1,277 binding antibody units/mL—a statistically significant difference. Overall, among participants who received two doses of an mRNA vaccine at the time of blood collection, antibody responses decreased over time after the most recent dose. However, among a subset of 60 participants who were followed over a five-month period, antibody levels increased 10-fold after a booster dose. Nearly all (98%) people with no history of vaccination or known exposure to the coronavirus had negative antibody results. It’s possible the remaining 2% may have had exposures or asymptomatic cases, Bohn said.
It’s not surprising that children would have higher antibodies as they are likely to have fewer comorbidities and more active immune systems, Bohn said. However, it’s worth noting that significant variation in antibody levels was observed across participants of similar ages. In light of this, she added that, “future work is needed to relate antibody presence to functional immune response as well as breakthrough infections.”
Prior COVID Infection, Lack of Hypertension Yield Higher Antibodies After mRNA Vaccines
Separate research led by Kimia Sobhani, PhD, of Cedars Sinai Medical Center in Los Angeles, studied characteristics associated with variable antibody responses to the Pfizer-BioNTech vaccine. Sobhani’s team measured the blood antibody levels of 843 healthcare workers at the medical center for 10 months after participants completed a two-dose vaccine regimen. Participants submitted a health questionnaire and at least two blood samples for analysis.
For the duration of the study, 99.6% of individuals remained positive for vaccine-induced antibodies against the virus’s spike protein. Those with prior SARS-CoV-2 infection had higher antibodies, as did females and younger participants (i.e., those below the median cohort age of 42 years). Additionally, those who did not have hypertension had persistently higher antibodies. However, prior SARS-CoV-2 infection modified the associations of hypertension—i.e., participants who had not been infected and who had hypertension had persistently lower antibodies, while prior-infected individuals who had hypertension exhibited relatively higher antibodies that remained higher over time.
The findings offer insights into factors that may influence “hybrid” immunity brought about by natural infection combined with vaccination, Sobhani said. “Everyone that we studied remained in the positive range for antibodies measured during the entire timeframe they were followed post-vaccination,” she said. “Whether that level of positivity is correlated to some degree of protection remains to be determined, because thresholds have not yet been validated or agreed upon.” She added that T cell responses also may provide insight, and are another area that her team plans to study.
Abstract Information
AACC Annual Scientific Meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc0722/media/landing.asp
Abstract A-077: Longitudinal analysis of characteristics associated with variable antibody response to BNT162b2 vaccination among healthcare workers over ten months will be presented during:
Scientific Poster Session
Tuesday, July 26
9:30 a.m. – 5 p.m. (presenting author in attendance from 1:30 – 2:30 p.m.)
Poster Hall, Clinical Lab Expo show floor
McCormick Place Convention Center
Chicago
About the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo
The AACC Annual Scientific Meeting offers 5 days packed with opportunities to learn about exciting science from July 24-28. Plenary sessions will explore artificial intelligence-based clinical prediction models, advances in multiplex technologies, human brain organogenesis, building trust between the public and healthcare experts, and direct mass spectrometry techniques.
At the AACC Clinical Lab Expo, more than 750 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago with displays of the latest diagnostic technology, including but not limited to COVID-19 testing, artificial intelligence, mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation.
About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.
